ID   ORML3_HUMAN             Reviewed;         153 AA.
AC   Q8N138; B3KS83; Q6UY83;
DT   08-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   28-JAN-2026, entry version 169.
DE   RecName: Full=ORM1-like protein 3;
GN   Name=ORMDL3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=12093374; DOI=10.1186/gb-2002-3-6-research0027;
RA   Hjelmqvist L., Tuson M., Marfany G., Herrero E., Balcells S.,
RA   Gonzalez-Duarte R.;
RT   "ORMDL proteins are a conserved new family of endoplasmic reticulum
RT   membrane proteins.";
RL   Genome Biol. 3:RESEARCH0027.1-RESEARCH0027.13(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Luoh S.-W., Venkatesan N., Slamon D.J.;
RT   "An evolutionarily conserved gene from the HER-2/Neu amplicon defines a
RT   novel gene family.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Li H., Yu R., Shen C., Zhou G., Ke R., Lin L., Yang S.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ASTHMA.
RX   PubMed=17611496; DOI=10.1038/nature06014;
RA   Moffatt M.F., Kabesch M., Liang L., Dixon A.L., Strachan D., Heath S.,
RA   Depner M., von Berg A., Bufe A., Rietschel E., Heinzmann A., Simma B.,
RA   Frischer T., Willis-Owen S.A., Wong K.C., Illig T., Vogelberg C.,
RA   Weiland S.K., von Mutius E., Abecasis G.R., Farrall M., Gut I.G.,
RA   Lathrop G.M., Cookson W.O.;
RT   "Genetic variants regulating ORMDL3 expression contribute to the risk of
RT   childhood asthma.";
RL   Nature 448:470-473(2007).
RN   [8]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ASTHMA.
RX   PubMed=18395550; DOI=10.1016/j.jaci.2008.01.015;
RA   Tavendale R., Macgregor D.F., Mukhopadhyay S., Palmer C.N.;
RT   "A polymorphism controlling ORMDL3 expression is associated with asthma
RT   that is poorly controlled by current medications.";
RL   J. Allergy Clin. Immunol. 121:860-863(2008).
RN   [9]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ASTHMA.
RX   PubMed=18760456; DOI=10.1016/j.jaci.2008.06.041;
RA   Sleiman P.M., Annaiah K., Imielinski M., Bradfield J.P., Kim C.E.,
RA   Frackelton E.C., Glessner J.T., Eckert A.W., Otieno F.G., Santa E.,
RA   Thomas K., Smith R.M., Glaberson W., Garris M., Gunnlaugsson S.,
RA   Chiavacci R.M., Allen J., Spergel J., Grundmeier R., Grunstein M.M.,
RA   Magnusson M., Bisgaard H., Grant S.F., Hakonarson H.;
RT   "ORMDL3 variants associated with asthma susceptibility in North Americans
RT   of European ancestry.";
RL   J. Allergy Clin. Immunol. 122:1225-1227(2008).
RN   [10]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ASTHMA.
RX   PubMed=19133921; DOI=10.1111/j.1398-9995.2008.01912.x;
RA   Wu H., Romieu I., Sienra-Monge J.J., Li H., del Rio-Navarro B.E.,
RA   London S.J.;
RT   "Genetic variation in ORM1-like 3 (ORMDL3) and gasdermin-like (GSDML) and
RT   childhood asthma.";
RL   Allergy 64:629-635(2009).
RN   [11]
RP   SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=19819884; DOI=10.1093/hmg/ddp471;
RA   Cantero-Recasens G., Fandos C., Rubio-Moscardo F., Valverde M.A.,
RA   Vicente R.;
RT   "The asthma-associated ORMDL3 gene product regulates endoplasmic reticulum-
RT   mediated calcium signaling and cellular stress.";
RL   Hum. Mol. Genet. 19:111-121(2010).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH SPTLC1.
RX   PubMed=20182505; DOI=10.1038/nature08787;
RA   Breslow D.K., Collins S.R., Bodenmiller B., Aebersold R., Simons K.,
RA   Shevchenko A., Ejsing C.S., Weissman J.S.;
RT   "Orm family proteins mediate sphingolipid homeostasis.";
RL   Nature 463:1048-1053(2010).
RN   [13]
RP   FUNCTION.
RX   PubMed=30700557; DOI=10.1074/jbc.ra118.007291;
RA   Davis D.L., Gable K., Suemitsu J., Dunn T.M., Wattenberg B.W.;
RT   "The ORMDL/Orm-serine palmitoyltransferase (SPT) complex is directly
RT   regulated by ceramide: Reconstitution of SPT regulation in isolated
RT   membranes.";
RL   J. Biol. Chem. 294:5146-5156(2019).
RN   [14]
RP   UBIQUITINATION, HYDROXYLATION AT PRO-137, AND MUTAGENESIS OF PRO-137.
RX   PubMed=36408842; DOI=10.15252/embr.202254689;
RA   Sasset L., Chowdhury K.H., Manzo O.L., Rubinelli L., Konrad C.,
RA   Maschek J.A., Manfredi G., Holland W.L., Di Lorenzo A.;
RT   "Sphingosine-1-phosphate controls endothelial sphingolipid homeostasis via
RT   ORMDL.";
RL   EMBO Rep. 24:e54689-e54689(2023).
RN   [15] {ECO:0007744|PDB:7K0M, ECO:0007744|PDB:7K0N, ECO:0007744|PDB:7K0O, ECO:0007744|PDB:7K0P, ECO:0007744|PDB:7K0Q}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.60 ANGSTROMS) IN COMPLEX WITH SPTLC1;
RP   SPTLC2 AND SPTSSA.
RX   PubMed=33558761; DOI=10.1038/s41594-020-00551-9;
RA   Wang Y., Niu Y., Zhang Z., Gable K., Gupta S.D., Somashekarappa N., Han G.,
RA   Zhao H., Myasnikov A.G., Kalathur R.C., Dunn T.M., Lee C.H.;
RT   "Structural insights into the regulation of human serine
RT   palmitoyltransferase complexes.";
RL   Nat. Struct. Mol. Biol. 28:240-248(2021).
RN   [16] {ECO:0007744|PDB:6M4N, ECO:0007744|PDB:6M4O, ECO:0007744|PDB:7CQI, ECO:0007744|PDB:7CQK}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS) IN COMPLEX WITH SPTLC1;
RP   SPTSSA AND ORMDL3, AND TOPOLOGY.
RX   PubMed=33558762; DOI=10.1038/s41594-020-00553-7;
RA   Li S., Xie T., Liu P., Wang L., Gong X.;
RT   "Structural insights into the assembly and substrate selectivity of human
RT   SPT-ORMDL3 complex.";
RL   Nat. Struct. Mol. Biol. 28:249-257(2021).
RN   [17] {ECO:0007744|PDB:7YIU, ECO:0007744|PDB:7YIY, ECO:0007744|PDB:7YJ1, ECO:0007744|PDB:7YJ2}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.70 ANGSTROMS) IN COMPLEX WITH SPTLC1;
RP   SPTLC2 AND SPTSSA, DOMAIN, FUNCTION, AND MUTAGENESIS OF 2-ASN--MET-17;
RP   2-ASN--SER-8; ASN-2; ASN-13; VAL-16; ILE-22; PHE-63 AND HIS-85.
RX   PubMed=37308477; DOI=10.1038/s41467-023-39274-y;
RA   Xie T., Liu P., Wu X., Dong F., Zhang Z., Yue J., Mahawar U., Farooq F.,
RA   Vohra H., Fang Q., Liu W., Wattenberg B.W., Gong X.;
RT   "Ceramide sensing by human SPT-ORMDL complex for establishing sphingolipid
RT   homeostasis.";
RL   Nat. Commun. 14:3475-3475(2023).
CC   -!- FUNCTION: Plays an essential role in the homeostatic regulation of
CC       sphingolipid de novo biosynthesis by modulating the activity of the
CC       serine palmitoyltransferase (SPT) in response to ceramide levels
CC       (PubMed:20182505, PubMed:30700557, PubMed:37308477). When complexed to
CC       SPT, the binding of ceramides to its N-terminus stabilizes a
CC       conformation that block SPT substrate entry, hence preventing SPT
CC       catalytic activity. Through this mechanism, maintains ceramide levels
CC       at sufficient concentrations for the production of complex
CC       sphingolipids, but which prevents the accumulation of ceramides to
CC       levels that trigger apoptosis (PubMed:37308477).
CC       {ECO:0000269|PubMed:20182505, ECO:0000269|PubMed:30700557,
CC       ECO:0000269|PubMed:37308477}.
CC   -!- SUBUNIT: Ceramide-sensitive subunit of the serine palmitoyltransferase
CC       (SPT) complex, which is also composed of SPTLC1, SPTLC2/3 and SPTSSA/B.
CC       {ECO:0000269|PubMed:20182505, ECO:0000269|PubMed:33558761,
CC       ECO:0000269|PubMed:33558762, ECO:0000269|PubMed:37308477}.
CC   -!- INTERACTION:
CC       Q8N138; Q13520: AQP6; NbExp=3; IntAct=EBI-721750, EBI-13059134;
CC       Q8N138; Q3SXY8: ARL13B; NbExp=3; IntAct=EBI-721750, EBI-11343438;
CC       Q8N138; Q8IYJ2-2: C10orf67; NbExp=3; IntAct=EBI-721750, EBI-13381098;
CC       Q8N138; Q8IU89: CERS3; NbExp=3; IntAct=EBI-721750, EBI-18202821;
CC       Q8N138; Q8NI60: COQ8A; NbExp=3; IntAct=EBI-721750, EBI-745535;
CC       Q8N138; Q15125: EBP; NbExp=3; IntAct=EBI-721750, EBI-3915253;
CC       Q8N138; Q9GZR5: ELOVL4; NbExp=3; IntAct=EBI-721750, EBI-18535450;
CC       Q8N138; Q9Y282: ERGIC3; NbExp=3; IntAct=EBI-721750, EBI-781551;
CC       Q8N138; Q5JX71: FAM209A; NbExp=3; IntAct=EBI-721750, EBI-18304435;
CC       Q8N138; O00258: GET1; NbExp=3; IntAct=EBI-721750, EBI-18908258;
CC       Q8N138; Q96P66: GPR101; NbExp=3; IntAct=EBI-721750, EBI-17935713;
CC       Q8N138; Q8TDT2: GPR152; NbExp=3; IntAct=EBI-721750, EBI-13345167;
CC       Q8N138; Q7Z5P4: HSD17B13; NbExp=3; IntAct=EBI-721750, EBI-18053395;
CC       Q8N138; O95279: KCNK5; NbExp=3; IntAct=EBI-721750, EBI-3934936;
CC       Q8N138; O95214: LEPROTL1; NbExp=3; IntAct=EBI-721750, EBI-750776;
CC       Q8N138; Q9H2K0: MTIF3; NbExp=3; IntAct=EBI-721750, EBI-3923617;
CC       Q8N138; Q9BRK0: REEP2; NbExp=3; IntAct=EBI-721750, EBI-11337973;
CC       Q8N138; Q86VR2: RETREG3; NbExp=3; IntAct=EBI-721750, EBI-10192441;
CC       Q8N138; Q99942: RNF5; NbExp=3; IntAct=EBI-721750, EBI-348482;
CC       Q8N138; Q03395: ROM1; NbExp=3; IntAct=EBI-721750, EBI-9395257;
CC       Q8N138; Q14973: SLC10A1; NbExp=3; IntAct=EBI-721750, EBI-3923031;
CC       Q8N138; Q9NQQ7-3: SLC35C2; NbExp=3; IntAct=EBI-721750, EBI-17295964;
CC       Q8N138; P30825: SLC7A1; NbExp=3; IntAct=EBI-721750, EBI-4289564;
CC       Q8N138; O15269: SPTLC1; NbExp=6; IntAct=EBI-721750, EBI-1044323;
CC       Q8N138; Q8N9I0: SYT2; NbExp=3; IntAct=EBI-721750, EBI-8032987;
CC       Q8N138; Q96Q45-2: TMEM237; NbExp=3; IntAct=EBI-721750, EBI-10982110;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:12093374, ECO:0000269|PubMed:19819884}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:12093374,
CC       ECO:0000269|PubMed:19819884, ECO:0000269|PubMed:33558762}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8N138-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8N138-4; Sequence=VSP_016052;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expressed in adult and fetal
CC       heart, brain, lung, liver, skeletal muscle and kidney. Expressed in
CC       adult pancreas and placenta and in fetal spleen and thymus.
CC       {ECO:0000269|PubMed:12093374}.
CC   -!- DOMAIN: Ceramides bind to ORMDL3 N-terminus and stabilize it in a
CC       conformation that physically restricts the accessibility of the
CC       substrates to their binding sites in the serine palmitoyltransferase
CC       (SPT) complex, hence inhibiting SPT catalytic activity. In the absence
CC       of ceramides, the N-terminus is flexible and permits substrate binding,
CC       thus liberating SPT from inhibition. {ECO:0000269|PubMed:33558761,
CC       ECO:0000269|PubMed:37308477}.
CC   -!- PTM: When hydroxylated at Pro-137, ubiquitinated via 'Lys-48'-linkage,
CC       leading to proteasomal degradation. In endothelial cells, ORMDL3
CC       proteasomal degradation is controlled by the sphingosine 1-phosphate
CC       receptor signaling pathway. {ECO:0000269|PubMed:36408842}.
CC   -!- DISEASE: Asthma (ASTHMA) [MIM:600807]: The most common chronic disease
CC       affecting children and young adults. It is a complex genetic disorder
CC       with a heterogeneous phenotype, largely attributed to the interactions
CC       among many genes and between these genes and the environment. It is
CC       characterized by recurrent attacks of paroxysmal dyspnea, with wheezing
CC       due to spasmodic contraction of the bronchi.
CC       {ECO:0000269|PubMed:18395550, ECO:0000269|PubMed:18760456,
CC       ECO:0000269|PubMed:19133921}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry. SNPs on
CC       17q21 locus that are associated with childhood asthma also show a
CC       consistent and strong association with transcript levels of ORMDL3,
CC       indicating that genetic variants regulating ORMDL3 expression are
CC       determinants of susceptibility to childhood asthma.
CC       {ECO:0000269|PubMed:17611496}.
CC   -!- SIMILARITY: Belongs to the ORM family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF395708; AAM43507.1; -; mRNA.
DR   EMBL; AF373101; AAN76521.1; -; mRNA.
DR   EMBL; AF373102; AAN76522.1; -; mRNA.
DR   EMBL; AK074811; BAC11223.1; -; mRNA.
DR   EMBL; AY357943; AAQ57273.1; -; mRNA.
DR   EMBL; AK075212; BAC11476.1; -; mRNA.
DR   EMBL; AK093063; BAG52645.1; -; mRNA.
DR   EMBL; CH471152; EAW60617.1; -; Genomic_DNA.
DR   EMBL; BC017087; AAH17087.1; -; mRNA.
DR   EMBL; BC071833; AAH71833.1; -; mRNA.
DR   CCDS; CCDS11355.1; -. [Q8N138-1]
DR   RefSeq; NP_001307730.1; NM_001320801.2. [Q8N138-1]
DR   RefSeq; NP_001307731.1; NM_001320802.2. [Q8N138-1]
DR   RefSeq; NP_001307732.1; NM_001320803.1. [Q8N138-1]
DR   RefSeq; NP_644809.1; NM_139280.4. [Q8N138-1]
DR   RefSeq; XP_047293049.1; XM_047437093.1. [Q8N138-1]
DR   RefSeq; XP_047293050.1; XM_047437094.1. [Q8N138-1]
DR   RefSeq; XP_047293051.1; XM_047437095.1. [Q8N138-1]
DR   RefSeq; XP_054173807.1; XM_054317832.1. [Q8N138-1]
DR   RefSeq; XP_054173808.1; XM_054317833.1. [Q8N138-1]
DR   PDB; 6M4N; EM; 3.80 A; C/G=1-153.
DR   PDB; 6M4O; EM; 3.40 A; A=1-153.
DR   PDB; 7CQI; EM; 3.20 A; A=1-153.
DR   PDB; 7CQK; EM; 3.30 A; A=1-153.
DR   PDB; 7K0M; EM; 2.90 A; D/H=1-153.
DR   PDB; 7K0N; EM; 3.10 A; D/H=1-153.
DR   PDB; 7K0O; EM; 3.10 A; D/H=1-153.
DR   PDB; 7K0P; EM; 3.10 A; D/H=1-153.
DR   PDB; 7K0Q; EM; 3.30 A; D=1-153.
DR   PDB; 7YIU; EM; 2.90 A; D=1-153.
DR   PDB; 7YIY; EM; 2.70 A; D=1-153.
DR   PDB; 7YJ1; EM; 3.10 A; D=3-153.
DR   PDB; 7YJ2; EM; 2.90 A; D=1-153.
DR   PDBsum; 6M4N; -.
DR   PDBsum; 6M4O; -.
DR   PDBsum; 7CQI; -.
DR   PDBsum; 7CQK; -.
DR   PDBsum; 7K0M; -.
DR   PDBsum; 7K0N; -.
DR   PDBsum; 7K0O; -.
DR   PDBsum; 7K0P; -.
DR   PDBsum; 7K0Q; -.
DR   PDBsum; 7YIU; -.
DR   PDBsum; 7YIY; -.
DR   PDBsum; 7YJ1; -.
DR   PDBsum; 7YJ2; -.
DR   AlphaFoldDB; Q8N138; -.
DR   EMDB; EMD-22602; -.
DR   EMDB; EMD-22604; -.
DR   EMDB; EMD-22605; -.
DR   EMDB; EMD-22606; -.
DR   EMDB; EMD-22608; -.
DR   EMDB; EMD-30079; -.
DR   EMDB; EMD-30080; -.
DR   EMDB; EMD-30441; -.
DR   EMDB; EMD-30442; -.
DR   EMDB; EMD-33864; -.
DR   EMDB; EMD-33866; -.
DR   EMDB; EMD-33868; -.
DR   EMDB; EMD-33869; -.
DR   SMR; Q8N138; -.
DR   BioGRID; 125114; 63.
DR   CORUM; Q8N138; -.
DR   DIP; DIP-48687N; -.
DR   FunCoup; Q8N138; 928.
DR   IntAct; Q8N138; 60.
DR   STRING; 9606.ENSP00000377724; -.
DR   iPTMnet; Q8N138; -.
DR   PhosphoSitePlus; Q8N138; -.
DR   BioMuta; ORMDL3; -.
DR   DMDM; 74728486; -.
DR   jPOST; Q8N138; -.
DR   MassIVE; Q8N138; -.
DR   PaxDb; 9606-ENSP00000377724; -.
DR   PeptideAtlas; Q8N138; -.
DR   ProteomicsDB; 71543; -. [Q8N138-1]
DR   ProteomicsDB; 71544; -. [Q8N138-4]
DR   Pumba; Q8N138; -.
DR   TopDownProteomics; Q8N138-1; -. [Q8N138-1]
DR   Antibodypedia; 54876; 114 antibodies from 23 providers.
DR   DNASU; 94103; -.
DR   Ensembl; ENST00000304046.7; ENSP00000304858.2; ENSG00000172057.11. [Q8N138-1]
DR   Ensembl; ENST00000394169.5; ENSP00000377724.1; ENSG00000172057.11. [Q8N138-1]
DR   Ensembl; ENST00000579695.5; ENSP00000464693.1; ENSG00000172057.11. [Q8N138-1]
DR   Ensembl; ENST00000584220.5; ENSP00000464455.1; ENSG00000172057.11. [Q8N138-4]
DR   GeneID; 94103; -.
DR   KEGG; hsa:94103; -.
DR   MANE-Select; ENST00000304046.7; ENSP00000304858.2; NM_139280.4; NP_644809.1.
DR   UCSC; uc002htj.3; human. [Q8N138-1]
DR   AGR; HGNC:16038; -.
DR   ClinPGx; PA32821; -.
DR   CTD; 94103; -.
DR   DisGeNET; 94103; -.
DR   GeneCards; ORMDL3; -.
DR   HGNC; HGNC:16038; ORMDL3.
DR   HPA; ENSG00000172057; Tissue enhanced (liver).
DR   MIM; 600807; phenotype.
DR   MIM; 610075; gene.
DR   OpenTargets; ENSG00000172057; -.
DR   VEuPathDB; HostDB:ENSG00000172057; -.
DR   eggNOG; KOG3319; Eukaryota.
DR   GeneTree; ENSGT00950000183178; -.
DR   HOGENOM; CLU_072117_3_0_1; -.
DR   InParanoid; Q8N138; -.
DR   OMA; WTAYILI; -.
DR   OrthoDB; 1932233at2759; -.
DR   PAN-GO; Q8N138; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; Q8N138; -.
DR   PathwayCommons; Q8N138; -.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; Q8N138; -.
DR   Agora; ENSG00000172057; -.
DR   BioGRID-ORCS; 94103; 17 hits in 1164 CRISPR screens.
DR   ChiTaRS; ORMDL3; human.
DR   GenomeRNAi; 94103; -.
DR   Pharos; Q8N138; Tbio.
DR   PRO; PR:Q8N138; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q8N138; protein.
DR   Bgee; ENSG00000172057; Expressed in right lobe of liver and 179 other cell types or tissues.
DR   ExpressionAtlas; Q8N138; baseline and differential.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0017059; C:serine palmitoyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0006672; P:ceramide metabolic process; IMP:UniProtKB.
DR   GO; GO:0090156; P:intracellular sphingolipid homeostasis; IBA:GO_Central.
DR   GO; GO:0061744; P:motor behavior; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0002903; P:negative regulation of B cell apoptotic process; IMP:MGI.
DR   GO; GO:1900060; P:negative regulation of ceramide biosynthetic process; IMP:MGI.
DR   GO; GO:0010508; P:positive regulation of autophagy; IDA:MGI.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IDA:MGI.
DR   GO; GO:0006940; P:regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006686; P:sphingomyelin biosynthetic process; IEA:Ensembl.
DR   InterPro; IPR007203; ORMDL.
DR   PANTHER; PTHR12665; ORMDL PROTEINS; 1.
DR   Pfam; PF04061; ORMDL; 1.
DR   PIRSF; PIRSF018147; ORMDL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Asthma; Endoplasmic reticulum;
KW   Hydroxylation; Membrane; Proteomics identification; Reference proteome;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..153
FT                   /note="ORM1-like protein 3"
FT                   /id="PRO_0000215639"
FT   TOPO_DOM        1..21
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        22..44
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:33558762,
FT                   ECO:0007744|PDB:6M4N, ECO:0007744|PDB:6M4O,
FT                   ECO:0007744|PDB:7CQI, ECO:0007744|PDB:7CQK"
FT   TRANSMEM        45..63
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:33558762,
FT                   ECO:0007744|PDB:6M4N, ECO:0007744|PDB:6M4O,
FT                   ECO:0007744|PDB:7CQI, ECO:0007744|PDB:7CQK"
FT   TOPO_DOM        64..100
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        101..117
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:33558762,
FT                   ECO:0007744|PDB:6M4N, ECO:0007744|PDB:6M4O,
FT                   ECO:0007744|PDB:7CQI, ECO:0007744|PDB:7CQK"
FT   TOPO_DOM        118..121
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        122..139
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:33558762,
FT                   ECO:0007744|PDB:6M4N, ECO:0007744|PDB:6M4O,
FT                   ECO:0007744|PDB:7CQI, ECO:0007744|PDB:7CQK"
FT   TOPO_DOM        140..153
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..17
FT                   /note="Important for ceramide level-sensing"
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MOD_RES         137
FT                   /note="Hydroxyproline"
FT                   /evidence="ECO:0000269|PubMed:36408842"
FT   VAR_SEQ         43..58
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_016052"
FT   MUTAGEN         2..17
FT                   /note="Missing: Impaired negative regulation of SPT complex
FT                   activity in the presence of ceramides."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         2..8
FT                   /note="Missing: Impaired negative regulation of SPT complex
FT                   activity in the presence of ceramides."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         2
FT                   /note="Missing: Impaired negative regulation of SPT complex
FT                   activity in the presence of ceramides."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         13
FT                   /note="N->A: Disrupted ceramide binding; impaired negative
FT                   regulation of SPT complex activity in the presence of
FT                   ceramides; in the absence of ceramides, reduced affinity of
FT                   SPT complex towards palmitoyl-CoA."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         16
FT                   /note="V->R: Impaired negative regulation of SPT complex
FT                   activity in the presence of ceramides."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         22
FT                   /note="I->R: Impaired negative regulation of SPT complex
FT                   activity in the presence of ceramides."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         63
FT                   /note="F->P: Impaired negative regulation of SPT complex
FT                   activity in the presence of ceramides."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         63
FT                   /note="F->R: Impaired negative regulation of SPT complex
FT                   activity in the presence of ceramides."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         85
FT                   /note="H->A: No effect on the negative regulation of SPT
FT                   complex activity in the presence of ceramides."
FT                   /evidence="ECO:0000269|PubMed:37308477"
FT   MUTAGEN         137
FT                   /note="P->A: Increased protein levels; decreased
FT                   ubiquitination; increased negative regulation of SPT
FT                   complex activity."
FT                   /evidence="ECO:0000269|PubMed:36408842"
FT   HELIX           12..14
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           16..18
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           22..38
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   STRAND          40..42
FT                   /evidence="ECO:0007829|PDB:7K0Q"
FT   HELIX           45..65
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   STRAND          67..69
FT                   /evidence="ECO:0007829|PDB:7K0Q"
FT   STRAND          71..73
FT                   /evidence="ECO:0007829|PDB:7YJ2"
FT   TURN            75..77
FT                   /evidence="ECO:0007829|PDB:7K0P"
FT   TURN            79..82
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           85..88
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           89..92
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   STRAND          93..95
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           97..115
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   TURN            116..118
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           121..132
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   TURN            133..135
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           136..138
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           140..142
FT                   /evidence="ECO:0007829|PDB:7YIY"
FT   HELIX           147..149
FT                   /evidence="ECO:0007829|PDB:7YIY"
SQ   SEQUENCE   153 AA;  17495 MW;  3EF483CA5C03EC2E CRC64;
     MNVGTAHSEV NPNTRVMNSR GIWLSYVLAI GLLHIVLLSI PFVSVPVVWT LTNLIHNMGM
     YIFLHTVKGT PFETPDQGKA RLLTHWEQMD YGVQFTASRK FLTITPIVLY FLTSFYTKYD
     QIHFVLNTVS LMSVLIPKLP QLHGVRIFGI NKY
//
